10-Q: Indivior Q3 Net Income Soars Amid Strategic Restructuring

Indivior PLC reported a significant increase in net income for Q3 2025, driven by strong SUBLOCADE sales and ongoing strategic restructuring initiatives.

Summary

• Net income for the three months ended September 30, 2025, increased to $42 million from $22 million in the prior year.
• Net income for the nine months ended September 30, 2025, significantly improved to $108 million compared to a net loss of $14 million in the same period of 2024.
• SUBLOCADE net revenue grew by 15% globally to $219 million for the quarter and 8% to $604 million for the nine months ended September 30, 2025.
• The company initiated Phase 1 of its "Indivior Action Agenda," incurring $35 million in corporate initiative transition costs during Q3 2025.
• Sales and marketing support for OPVEE was discontinued in Q3 2025, resulting in $37 million in related costs.
• Plans were announced in October 2025 to optimize the Rest of World (ROW) business by exiting several non-U.S. markets, with expected charges of $30 million to $50 million.
• The company delisted from the London Stock Exchange in July 2025, now trading exclusively on Nasdaq.
• A U.S. shareholder class action lawsuit was dismissed on September 15, 2025, with no appeal filed.

Sentiment

Score: 7

Explanation: The company demonstrated strong financial performance with significant increases in net income and EPS, primarily driven by SUBLOCADE. Strategic restructuring and cost-cutting measures are underway, and a major U.S. lawsuit was dismissed. However, ongoing litigation, declining revenue from other products, and negative working capital remain areas of concern.

Positives

• Net income for the three months ended September 30, 2025, increased by $20 million to $42 million, up from $22 million in the prior year.
• Net income for the nine months ended September 30, 2025, improved significantly to $108 million, compared to a net loss of $14 million in the same period of 2024.
• Basic earnings per share for the quarter increased to $0.34 from $0.16, and for the nine months to $0.87 from a loss of $0.11.
• SUBLOCADE net revenue (U.S. and Rest of World) increased by 15% to $219 million for the three months and 8% to $604 million for the nine months ended September 30, 2025.
• Net cash provided by operating activities for the nine months ended September 30, 2025, increased by $141 million to $194 million.
• The U.S. shareholder class action lawsuit was dismissed on September 15, 2025, with no appeal filed by the deadline.
• The company was in compliance with all debt covenants at September 30, 2025.
• The U.K. HMRC settlement is expected to be treated as a covered tax, effectively eliminating Pillar II top-up tax expense for the year, and is not expected to recur.

Negatives

• Gross profit for the three months ended September 30, 2025, decreased by $11 million to $230 million, and gross margin declined to 73% from 79% in the prior year quarter.
• Net revenue for the nine months ended September 30, 2025, decreased by $8 million, or 1%, to $881 million.
• U.S. net revenue from sublingual & other products declined by 17% for the quarter and 16% for the nine months due to increased competitive activity, lower pricing, and market share for SUBOXONE Film.
• OPVEE net revenue declined by 49% for the quarter and 48% for the nine months, and PERSERIS net revenue declined by 18% for the quarter and 40% for the nine months.
• Selling, general and administrative expenses increased by $13 million (9%) for the quarter and $8 million (2%) for the nine months, partly due to corporate initiative transition costs and SUBLOCADE marketing investments.
• Research and development expenses increased by $11 million (48%) for the quarter, including $13 million in restructuring and impairment costs.
• Accrued litigation settlement expenses remain substantial at $406 million as of September 30, 2025.
• Current liabilities exceed current assets by $43 million, and total liabilities exceed total assets by $207 million.

Risks

• Regulatory uncertainties from the "One Big Beautiful Bill Act" (OBBBA) enacted in July 2025 could impact the business, potentially leading to deprioritization of innovative or higher-cost treatments, changes to Medicaid funding and eligibility rules, and work or community engagement standards for ACA-eligible adults.
• The CMS finalized the Marketplace Integrity and Affordability Regulation in June 2025, which modifies ACA exchange open enrollment periods and eligibility for premium tax credits, potentially affecting patient access to treatment.
• Ongoing civil opioid litigation, including private plaintiff cases not covered by current settlements, poses an unquantifiable risk of loss.
• Numerous lawsuits alleging SUBOXONE Film caused dental injury and failure to warn, with over 1,900 cases in the Dental MDL and additional state court and proposed class actions, present significant unquantifiable litigation risk.
• U.K. shareholder claims alleging violations of the FSMA 2000 by making false or misleading statements regarding the SUBOXONE Tablet to Film switch represent ongoing litigation with an unquantifiable possible loss.
• The company's ability to sustain sales volume performance and maintain necessary liquidity is dependent on no material change in the timing of collections and rebate payments.

Future Outlook

Expects incremental growth from new products to continue to more than offset net revenue declines in the legacy tablet business in 2025. Rest of World net revenue will be impacted by plans to exit several non-U.S. markets, though continuing operations represent 77% of forecasted ROW net revenue. Research and development expenses are expected to continue to track below 2024 levels through the remainder of the year, excluding restructuring impacts. Anticipates $45 million to $55 million in capital expenditures for the full year 2025 and an additional $35 million to $45 million in 2026, primarily for the Raleigh Manufacturing Facility SUBLOCADE suite. The company will continue evaluating investment opportunities in commercial stage assets, with no current commitments. Believes existing cash, cash equivalents, investments, and cash generated from operations will meet anticipated cash needs for at least the next twelve months. The opt-in process for civil opioid litigation settlements is not expected to be complete before the end of January 2026. The U.K. HMRC settlement and resulting Pillar II elimination are not expected to recur in future periods. Does not anticipate material impacts from the "One Big Beautiful Bill Act" (OBBBA) tax law changes.

Management Comments

• Our vision is that all patients will have access to evidence-based treatment for OUD and we are dedicated to transforming OUD from a human crisis to a recognized and treated chronic disease.
• We expect incremental growth from new products to continue to more than offset net revenue declines in the legacy tablet business in 2025, though Rest of World net revenue will be impacted by our plans to exit several non-U.S. markets.
• The Company believes its existing cash and cash equivalents and investments together with cash generated from operations and debt will enable its anticipated cash needs to be met... for at least the twelve-month period following the issuance of this Form 10-Q.
• The Company will need to sustain sales volume performance with no material change in the timing of its collections and rebate payments to maintain necessary liquidity in the near term and to meet our obligations in the long term.

Industry Context

The company operates in the pharmaceutical sector, specifically focusing on opioid use disorder (OUD) treatments. The strong performance of SUBLOCADE indicates continued demand and market acceptance for long-acting buprenorphine formulations in OUD treatment. The discontinuation of OPVEE sales and marketing support and the optimization of the Rest of World business reflect a strategic focus on core OUD products and key markets, a common trend in the pharmaceutical industry to streamline operations and maximize returns on successful assets. The ongoing litigation related to opioids and SUBOXONE Film highlights the significant legal and regulatory scrutiny faced by pharmaceutical companies involved in pain management and addiction treatment, a pervasive industry challenge. Regulatory changes like the OBBBA and CMS regulations indicate an evolving healthcare policy landscape in the U.S., which could impact patient access and reimbursement for pharmaceutical products, particularly those in specialized therapeutic areas like OUD.

Corporate Governance

Legal Proceedings

• Civil Opioid Litigation: Settlement terms reached for certain civil opioid litigation (cities, counties, tribal nations), with the tribal settlement complete. The opt-in process for subdivisions is ongoing and not expected to be complete before January 2026. A provision of $80 million has been recorded. Private plaintiff cases (e.g., neonatal abstinence syndrome) are not resolved by these settlements.
• Dental Allegations: Over 1,900 cases (22,500+ plaintiffs) in the Dental MDL and additional state court and proposed class actions allege SUBOXONE Film caused dental injury. The number of Schedule A claimants has been reduced to 8,035. The company intends to vigorously defend itself.
• U.K. Shareholder Claims: A multiparty action alleges violations of the U.K. Financial Services and Markets Act 2000 regarding alleged false or misleading statements related to the SUBOXONE Tablet to Film switch. The company served its defense on October 6, 2025.
• U.S. Shareholder Claims: A class action lawsuit alleging violations of U.S. federal securities laws was dismissed on September 15, 2025, and no appeal was filed by the deadline.

Stakeholder Impact

• Shareholders: Positive impact from increased net income and EPS, dismissal of U.S. shareholder lawsuit, and strategic focus. Potential negative impact from ongoing litigation risks and restructuring costs.
• Employees: Impacted by headcount reductions as part of the Indivior Action Agenda and ROW business optimization.
• Customers (Patients): Continued access to SUBLOCADE for OUD treatment. Discontinuation of OPVEE sales and marketing support may affect access to that product, though distribution will continue upon request.
• Suppliers: Potential impact from discontinuation of OPVEE sales and marketing and ROW business optimization, including contract terminations.
• Creditors: Company remains in compliance with debt covenants, and liquidity is deemed sufficient for the next 12 months, indicating stable creditworthiness.

Next Steps

• Complete the opt-in process for civil opioid litigation settlements, anticipated by the end of January 2026.
• Recognize the majority of charges related to ROW business optimization in Q4 2025 and Q1 2026.
• Continue to evaluate investment opportunities in commercial stage assets.
• Continue to defend against ongoing civil opioid litigation, dental allegations, and U.K. shareholder claims.
• Monitor the implementation of OBBBA provisions and CMS regulations, with most effective dates in 2027 and 2028.
• File Reply to Defence for U.K. multiparty action by November 17, 2025.

Key Dates

Recommendation

The company demonstrated a strong financial turnaround with significant net income and EPS growth, primarily driven by its flagship product, SUBLOCADE. Strategic restructuring initiatives, including the discontinuation of underperforming assets and optimization of international operations, are expected to streamline the business and enhance focus on core OUD treatments. The dismissal of a major U.S. shareholder lawsuit removes a significant overhang. While substantial litigation risks remain, the improved operational performance, strong cash generation from operations, and clear strategic direction suggest a positive outlook for long-term investors. The current negative working capital and total liabilities exceeding assets are noted, but management asserts sufficient liquidity for the foreseeable future.

Keywords

Opioid Use Disorder, SUBLOCADE, Pharmaceuticals, SEC Filing, 10-Q, Financial Results, Corporate Restructuring, Litigation, OUD Treatment, Nasdaq